Meningococcemia secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 12: Line 12:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Needs overview]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]

Revision as of 15:54, 15 February 2013

Meningococcemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningococcemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningococcemia secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningococcemia secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningococcemia secondary prevention

CDC on Meningococcemia secondary prevention

Meningococcemia secondary prevention in the news

Blogs on Meningococcemia secondary prevention

Directions to Hospitals Treating Meningococcemia

Risk calculators and risk factors for Meningococcemia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Secondary Prevention

The most important form of prevention is a vaccine against Neisseria meningitidis. Different countries have different strains of the bacteria and therefore use different vaccines. Five serogroups, A, B, C, Y and W135 are responsible for virtually all cases of the disease in humans. Vaccines are currently available against four of the five strains, and a vaccine against the B strain is in development. Menactra and Menomune are two commonly used vaccines. Unfortunately, there is currently no evidence that any of the current vaccines offer significant protection beyond three years.

Additionally, basic hygiene measures, such as hand washing and not sharing drinking cups, can reduce the incidence of infection by limiting exposure.

When a case is confirmed, all close contacts with the infected person can be offered antibiotics to reduce the likelihood of the infection spreading to other people.

References

Template:WH Template:WS